Henderson Mary Elizabeth 4
4 · Jazz Pharmaceuticals plc · Filed Mar 2, 2026
Research Summary
AI-generated summary of this filing
Jazz Pharmaceuticals SVP Mary Henderson Sells Shares
What Happened
Mary Elizabeth Henderson, Senior Vice President, Technical Operations at Jazz Pharmaceuticals (JAZZ), reported two transactions on 2026-02-26. She sold 5,343 ordinary shares in open-market transactions for a weighted average price of $194.49, generating $1,039,134 in proceeds. On the same date she was granted 4,447 restricted stock units (RSUs) (no immediate cash value reported).
Key Details
- Transaction dates: February 26, 2026; Form 4 filed March 2, 2026 (appears timely).
- Sale: 5,343 shares disposed, weighted average price $194.49, proceeds $1,039,134; reported sale prices ranged $194.19–$194.50.
- Grant: 4,447 RSUs granted (acquisition reported at $0 because RSUs convert to shares only upon vesting).
- Shares owned after transaction: not reported in the provided filing excerpt.
- Footnotes: F1 — RSUs issued under the 2011 Equity Incentive Plan and vest in equal annual installments over four years with a vesting commencement date of March 5, 2026. F2 — shares sold to satisfy tax obligations from vesting of previously granted RSUs. F3 — sale executed in multiple trades; weighted-average price reported with range provided.
Context
The sale was reported as a routine open-market disposal and — per the filing footnote — some sales were to satisfy tax withholding from prior RSU vesting, which is a common, non-directional reason insiders sell shares. The RSU grant represents future contingent share awards that will vest over four years rather than immediate share ownership.
Insider Transaction Report
- Award
Ordinary Shares
[F1]2026-02-26+4,447→ 34,071 total - Sale
Ordinary Shares
[F2][F3]2026-02-26$194.49/sh−5,343$1,039,134→ 28,728 total
Footnotes (3)
- [F1]These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2026, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.
- [F2]Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
- [F3]Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $194.1900 to $194.5000. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.